Pharmaceuticals, Biotechnology and Life Sciences
Galapagos NV announced on Tuesday three new Phase 2 Proof-of-Concept studies investigating filgotinib in Sjögren`s syndrome, ankylosing spondylitis, and psoriatic arthritis.
Verona Pharma has dosed the first patient in a phase 2a test of its candidate RPL554 for cystic fibrosis, the most common fatal inherited disease in the United States and Europe.
Shield Therapeutics will welcome new Chief Financial Officer to the Group, who will be a Board member, in the beginning of the month of May 2017.
Following innovation platforms on epigenetics and microbiome, BASF has created a third research platform on extraction and processes that already produces results.
Novartis has been cleared in Europe for Tafinlar combined with Mekinist (dabrafenib with trametinib) to treat patients with BRAF V600-with advanced non-small cell lung cancer (NSCLC).
InnovaDerma, a UK developer of life sciences, beauty and personal care products has secured new e-tailer distribution deals.
Avacta Group said on Monday that the first major immunogenicity study of Affimer technology using human ex-vivo samples was successful with a range of Affimer proteins shown to have low immunogenicity comparable with the marketed antibody Avastin.
Verona Pharma’s non-executive director Patrick Humphrey has decided to retire from the Board, effective April 15, 2017. The company said it doesn’t plan replacing him.
DBV Technologies, the Geneva University Hospitals (HUG) and BioNet-Asia have announced results from a Phase I trial assessing Viaskin rPT`s ability to boost immunity against pertussis by epicutaneously administering two doses of BioNet`s recombinant pertussis toxin.
Johnson & Johnson said its $30 billion tender offer for Swiss biotechnology company Actelion was successful, with the price of the offer being 280 per share for Actelion.